Impact of estroprogestin therapies on bone health from adolescence to postmenopause - PubMed
2 days ago
- #Estrogen-Progestin Therapies
- #Osteoporosis Prevention
- #Bone Health
- Estrogens play a crucial role in bone health throughout a woman's life, influencing skeletal growth in adolescence and bone remodeling in adulthood.
- Declining estrogen levels during perimenopause and postmenopause lead to bone mass loss, highlighting the importance of estrogen-progestin therapies.
- Combined oral contraceptives (COCs) are generally safe for bone mineral density (BMD) in adult women but require caution in adolescents, especially with low-dose estrogen formulations.
- Hormone replacement therapy (HRT) is essential for osteoporosis prevention in hypogonadal women, with transdermal estrogen at higher doses offering better bone protection.
- Oral GnRH receptor antagonists combined with add-back therapy provide a long-term option for managing uterine fibroids and endometriosis without affecting BMD.
- In postmenopausal women, both HRT and selective estrogen receptor modulators (SERMs) effectively reduce fracture risk and support bone health.
- Personalized treatment approaches are critical for balancing efficacy and safety in preserving bone health across a woman's lifespan.